Bloomberg Podcasts
@bloombergpodcasts·503K subscribers·32.4K videos
Novo, Lilly Fall as Trump Touts ‘Much Lower’ Ozempic Price
Posted
October 17, 2025
Views
1,089
Likes
11
Comments
3
Engagement
October 17, 2025
1,089
11
3
1.29%
Every word spoken in this episode is indexed. Type any phrase to jump straight to the moment it was said.
Type any word or phrase that may have been spoken. Click a result to seek the player to that exact moment.
Try a name, a topic, or a quoted line
See what was published immediately before and after this episode.
7:54Now PlayingNovo Nordisk and Eli Lilly shares fell after President Donald Trump said the price of the blockbuster diabetes drug Ozempic could come down to just $150 a month.
The US list price of Ozempic, which Trump called “the fat loss drug,” is roughly $1,000 for a month’s supply. Trump told reporters on Thursday that the cost of the drug, made by Novo, will soon be “much lower.” Lilly sells similar treatments, including Mounjaro and Zepbound. “Those are going to be $150 out of pocket,” he said during a press conference in the Oval Office. That could lead to a big hit for Novo and Lilly, the two companies dominating the market Wall Street expects to top $95 billion by 2030. Bloomberg News Health Reporter Madison Muller joins Bloomberg Businessweek Daily to discuss. She speaks with Carol Massar and Bailey Lipschultz.
--------
Watch Bloomberg Radio LIVE on YouTube
Weekdays 7am-6pm ET
Follow us on X
Subscribe to our Podcasts:
Bloomberg Daybreak
Bloomberg Surveillance
Bloomberg Intelligence
Balance of Power
Bloomberg Businessweek
Listen on Apple CarPlay and Android Auto with the Bloomberg Business app:
Apple CarPlay
Android Auto
Visit our YouTube channels:
Bloomberg Podcasts
Bloomberg Television
Bloomberg Originals
Sentinel Indexing in Progress
Metadata and chapters are available. Claim extraction for this episode is pending.
All video content is delivered via YouTube embedded players in accordance with the YouTube Terms of Service. Sentinel provides research tools that promote discovery and accountability across political media.
